JanOne Sells GeoTraq to SPYR Technologies in a $13.5 Million Transaction

Rhea-AI Summary

JanOne Inc. (Nasdaq: JAN) has sold the majority of its subsidiary, GeoTraq Inc., to SPYR Technologies Inc. for $13.5 million. The transaction involves cash and 30 million shares of SPYR's common stock. CEO Tony Isaac emphasized that this sale enables JanOne to concentrate on its primary business of developing non-addictive pain-relief drugs, particularly JAN101, aimed at treating peripheral artery disease (PAD). The sale is expected to assist in funding necessary clinical trials for JAN101.

Positive

• Sale of GeoTraq for $13.5 million bolsters financial resources.
• Focus on the development of JAN101 is expected to enhance growth potential.

Negative

• None.

Sale of GeoTraq allows JanOne to focus on core business strategy

LAS VEGAS, May 31, 2022 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), announced today that it has sold substantially all of the assets, and none of the liabilities, of GeoTraq Inc. ("GeoTraq"), its wholly-owned subsidiary, to SPYR Technologies Inc. ("SPYR").

"We believe this transaction further allows us to focus on our main business," said Tony Isaac CEO of JanOne. "Right now, our priority is the development of drugs with non-addictive, pain-relieving properties, specifically JAN101 (formerly known as TV1001SR), which is a potential treatment for peripheral artery disease (PAD). This sale of our subsidiary will help us continue to fund the necessary clinical trials for JAN101."  

Pursuant to the Asset Purchase Agreement, the aggregate purchase price for GeoTraq was $13.5 million, payable in cash and shares of SPYR's common stock. At closing, SPYR issued to JanOne 30,000,000 shares of its common stock and delivered to JanOne a five-year Promissory Note in the initial principal amount of $12.6 million. The Promissory Note bears simple interest at the rate of 8% per annum and  provides quarterly interest payments in arrears, which may be prepaid at any time without penalty.

About JanOne Inc.
JanOne Inc. is a unique Nasdaq-listed company offering innovative, actionable solutions that it believes can help create an end to the opioid crisis. JanOne Inc. is dedicated to funding resources toward innovation, technology and education to find a key resolution the national opioid epidemic, which is one of the deadliest and widespread in the country's history. The company continues to operate its legacy business – ARCA Recycling – under its current brand names. JanOne Inc's subsidiary, ARCA Recycling, recycles household appliances by providing turnkey recycling and replacement services for utilities and other sponsors of energy efficiency programs. Please visit www.janone.com for additional information.

Investor Relations & Media Contact
IR@Janone.com
1 (800) 400-224

View original content to download multimedia:https://www.prnewswire.com/news-releases/janone-sells-geotraq-to-spyr-technologies-in-a-13-5-million-transaction-301557566.html

SOURCE JanOne Inc.

FAQ

What was the sale price of GeoTraq by JanOne?

JanOne sold GeoTraq for $13.5 million.

How will the GeoTraq sale impact JanOne's business strategy?

The sale allows JanOne to concentrate on developing JAN101, a non-addictive pain relief drug.

What is JAN101 and its significance for JanOne?

JAN101 is a potential treatment for peripheral artery disease and is central to JanOne's business strategy.

What assets did JanOne sell to SPYR Technologies?

JanOne sold substantially all assets of GeoTraq, except for any liabilities.

What financial instruments did JanOne receive in the sale?

JanOne received 30 million shares of SPYR's common stock and a $12.6 million promissory note.